Protocol Ledger

NCT07502508 · Phase II · RECRUITING

Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy

Interventional Phase II clinical trial protocol NCT07502508 sponsored by Biomea Fusion in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-04-30 Enrollment: 60 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07502508
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)60 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07502508
Protocol FieldVerified Registry Value
NCT IdentifierNCT07502508
Consolidated Lead SponsorBiomea Fusion
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment60 participants (ESTIMATED)
Registered Start Date2026-04-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07502508
Hospital Research SiteLocationSite Profile
Hope Clinical ResearchCanoga Park, CAOpen Hospital Dossier ->
Ark Clinical ResearchLong Beach, CAOpen Hospital Dossier ->
Catalina Research Institute, LLCMontclair, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI